CARD14-Mediated Activation of Paracaspase MALT1 in Keratinocytes: Implications for Psoriasis

Journal of Investigative Dermatology

Volumn 137, Issue 3, 2017, Pages 569-575

  Van Nuffel, Elien ^a   Schmitt, Anja ^b   Afonina, Inna S ^a   Schulze Osthoff, Klaus ^b   Beyaert, Rudi ^a   Hailfinger, Stephan ^b  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE INHIBITOR; CASPASE RECRUITMENT DOMAIN CONTAINING PROTEIN 14; PARACASPASE MALT1; PROTEIN BCL 10; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; BCL10 PROTEIN, HUMAN; CARD14 PROTEIN, HUMAN; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; GUANYLATE CYCLASE; MALT1 PROTEIN, HUMAN; MEMBRANE PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR PROTEIN;

ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; KERATINOCYTE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PSORIASIS; REVIEW; ANIMAL; GENETICS; METABOLISM; MOUSE; MUTATION; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARD SIGNALING ADAPTOR PROTEINS; CASPASES; GUANYLATE CYCLASE; HUMANS; KERATINOCYTES; MEMBRANE PROTEINS; MICE; MUTATION; NEOPLASM PROTEINS; PSORIASIS; SIGNAL TRANSDUCTION;

EID: 85013942396     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1016/j.jid.2016.09.031     Document Type: Review

References (69)

1. Afonina, I.S., Elton, L., Carpentier, I., Beyaert, R., MALT1—a universal soldier: multiple strategies to ensure NF-kappaB activation and target gene expression. FEBS J 282 (2015), 3286–3297.
2. Afonina, I.S., Van Nuffel, E., Baudelet, G., Driege, Y., Kreike, M., Staal, J., et al. The paracaspase MALT1 mediates CARD14-induced signaling in keratinocytes. EMBO Rep 17 (2016), 914–927.
3. Ammar, M., Bouchlaka-Souissi, C., Helms, C.A., Zaraa, I., Jordan, C.T., Anbunathan, H., et al. Genome-wide linkage scan for psoriasis susceptibility loci in multiplex Tunisian families. Br J Dermatol 168 (2013), 583–587.
4. Ammar, M., Jordan, C.T., Cao, L., Lim, E., Bouchlaka Souissi, C., Jrad, A., et al. CARD14 alterations in Tunisian patients with psoriasis and further characterization in European cohorts. Br J Dermatol 174 (2016), 330–337.
5. Bertin, J., Wang, L., Guo, Y., Jacobson, M.D., Poyet, J.L., Srinivasula, S.M., et al. CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B. J Biol Chem 276 (2001), 11877–11882.
6. Bornancin, F., Renner, F., Touil, R., Sic, H., Kolb, Y., Touil-Allaoui, I., et al. Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation. J Immunol 194 (2015), 3723–3734.
7. Cabalzar, K., Pelzer, C., Wolf, A., Lenz, G., Iwaszkiewicz, J., Zoete, V., et al. Monoubiquitination and activity of the paracaspase MALT1 requires glutamate 549 in the dimerization interface. PLoS One, 8, 2013, e72051.
8. Coornaert, B., Baens, M., Heyninck, K., Bekaert, T., Haegman, M., Staal, J., et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol 9 (2008), 263–271.
9. Coto-Segura, P., Gonzalez-Fernandez, D., Batalla, A., Gomez, J., Gonzalez-Lara, L., Queiro, R., et al. Common and rare CARD14 gene variants affect the anti-TNF response among Psoriasis patients. Br J Dermatol 175 (2016), 134–141.
10. Deng, L., Wang, C., Spencer, E., Yang, L., Braun, A., You, J., et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103 (2000), 351–361.
11. Deng, Y., Chang, C., Lu, Q., The inflammatory response in psoriasis: a comprehensive review. Clin Rev Allergy Immunol 50 (2016), 377–389.
12. Eskin-Schwartz, M., Basel-Vanagaite, L., David, M., Lagovsky, I., Ben-Amitai, D., Smirin-Yosef, P., et al. Intra-familial variation in clinical phenotype of CARD14-related psoriasis. Acta Derm Venereol 96 (2016), 885–887.
13. Eytan, O., Sarig, O., Sprecher, E., van Steensel, M.A., Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14. Br J Dermatol 171 (2014), 420–422.
14. Feng, C., Wang, T., Li, S.J., Fan, Y.M., Shi, G., Zhu, K.J., CARD14 gene polymorphism c.C2458T (p.Arg820Trp) is associated with clinical features of psoriasis vulgaris in a Chinese cohort. J Dermatol 43 (2016), 294–297.
15. Fontan, L., Yang, C., Kabaleeswaran, V., Volpon, L., Osborne, M.J., Beltran, E., et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell 22 (2012), 812–824.
16. Fuchs-Telem, D., Sarig, O., van Steensel, M.A., Isakov, O., Israeli, S., Nousbeck, J., et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet 91 (2012), 163–170.
17. Gaide, O., Martinon, F., Micheau, O., Bonnet, D., Thome, M., Tschopp, J., Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF-kappaB activation. FEBS Lett 496 (2001), 121–127.
18. Gewies, A., Gorka, O., Bergmann, H., Pechloff, K., Petermann, F., Jeltsch, K.M., et al. Uncoupling Malt1 threshold function from paracaspase activity results in destructive autoimmune inflammation. Cell Rep 9 (2014), 1292–1305.
19. Gonzalez-Lara, L., Coto-Segura, P., Penedo, A., Eiris, N., Diaz, M., Santos-Juanes, J., et al. SNP rs11652075 in the CARD14 gene as a risk factor for psoriasis (PSORS2) in a Spanish cohort. DNA Cell Biol 32 (2013), 601–604.
20. Gross, O., Gewies, A., Finger, K., Schafer, M., Sparwasser, T., Peschel, C., et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 442 (2006), 651–656.
21. Hailfinger, S., Lenz, G., Thome, M., Targeting B-cell lymphomas with inhibitors of the MALT1 paracaspase. Curr Opin Chem Biol 23 (2014), 47–55.
22. Harden, J.L., Krueger, J.G., Bowcock, A.M., The immunogenetics of psoriasis: a comprehensive review. J Autoimmun 64 (2015), 66–73.
23. Harden, J.L., Lewis, S.M., Pierson, K.C., Suarez-Farinas, M., Lentini, T., Ortenzio, F.S., et al. CARD14 expression in dermal endothelial cells in psoriasis. PLoS One, 9, 2014, e111255.
24. Has, C., Schwieger-Briel, A., Schlipf, N., Hausser, I., Chmel, N., Rosler, B., et al. Target-sequence capture and high throughput sequencing identify a de novo CARD14 mutation in an infant with erythrodermic pityriasis rubra pilaris. Acta Derm Venereol 96 (2016), 989–990.
25. Howes, A., O'Sullivan, P.A., Breyer, F., Ghose, A., Cao, L., Krappmann, D., et al. Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-kappaB activation. Biochem J 473 (2016), 1759–1768.
26. Hulpiau, P., Driege, Y., Staal, J., Beyaert, R., MALT1 is not alone after all: identification of novel paracaspases. Cell Mol Life Sci 73 (2016), 1103–1116.
27. Inoue, N., Dainichi, T., Fujisawa, A., Nakano, H., Sawamura, D., Kabashima, K., CARD14 Glu138 mutation in familial pityriasis rubra pilaris does not warrant differentiation from familial psoriasis. J Dermatol 43 (2016), 187–189.
28. Jaworski, M., Marsland, B.J., Gehrig, J., Held, W., Favre, S., Luther, S.A., et al. Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity. EMBO J 33 (2014), 2765–2781.
29. Jordan, C.T., Cao, L., Roberson, E.D., Duan, S., Helms, C.A., Nair, R.P., et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet 90 (2012), 796–808.
30. Jordan, C.T., Cao, L., Roberson, E.D., Pierson, K.C., Yang, C.F., Joyce, C.E., et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet 90 (2012), 784–795.
31. Klein, T., Fung, S.Y., Renner, F., Blank, M.A., Dufour, A., Kang, S., et al. The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-kappaB signalling. Nat Commun, 6, 2015, 8777.
32. Korber, A., Mossner, R., Renner, R., Sticht, H., Wilsmann-Theis, D., Schulz, P., et al. Mutations in IL36RN in patients with generalized pustular psoriasis. J Invest Dermatol 133 (2013), 2634–2637.
33. Li, Q., Jin Chung, H., Ross, N., Keller, M., Andrews, J., Kingman, J., et al. Analysis of CARD14 polymorphisms in pityriasis rubra pilaris: activation of NF-kappaB. J Invest Dermatol 135 (2015), 1905–1908.
34. Lim, S.M., Jeong, Y., Lee, S., Im, H., Tae, H.S., Kim, B.G., et al. Identification of beta-lapachone analogs as novel MALT1 inhibitors to treat an aggressive subtype of diffuse large B-cell lymphoma. J Med Chem 58 (2015), 8491–8502.
35. Lowes, M.A., Suarez-Farinas, M., Krueger, J.G., Immunology of psoriasis. Annu Rev Immunol 32 (2014), 227–255.
36. Lucas, P.C., Yonezumi, M., Inohara, N., McAllister-Lucas, L.M., Abazeed, M.E., Chen, F.F., et al. Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway. J Biol Chem 276 (2001), 19012–19019.
37. Matsumoto, R., Wang, D., Blonska, M., Li, H., Kobayashi, M., Pappu, B., et al. Phosphorylation of CARMA1 plays a critical role in T cell receptor-mediated NF-kappaB activation. Immunity 23 (2005), 575–585.
38. Mc Guire, C., Elton, L., Wieghofer, P., Staal, J., Voet, S., Demeyer, A., et al. Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis. J Neuroinflammation, 11, 2014, 124.
39. McAllister-Lucas, L.M., Inohara, N., Lucas, P.C., Ruland, J., Benito, A., Li, Q., et al. Bimp1, a MAGUK family member linking protein kinase C activation to Bcl10-mediated NF-kappaB induction. J Biol Chem 276 (2001), 30589–30597.
40. Mease, P.J., Gladman, D.D., Papp, K.A., Khraishi, M.M., Thaci, D., Behrens, F., et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 69 (2013), 729–735.
41. Mossner, R., Frambach, Y., Wilsmann-Theis, D., Lohr, S., Jacobi, A., Weyergraf, A., et al. Palmoplantar pustular psoriasis is associated with missense variants in CARD14, but not with loss-of-function mutations in IL36RN in European patients. J Invest Dermatol 135 (2015), 2538–2541.
42. Nagel, D., Spranger, S., Vincendeau, M., Grau, M., Raffegerst, S., Kloo, B., et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer cell 22 (2012), 825–837.
43. Nestle, F.O., Kaplan, D.H., Barker, J., Psoriasis. N Engl J Med 361 (2009), 496–509.
44. Nititham, J., Taylor, K.E., Gupta, R., Chen, H., Ahn, R., Liu, J., et al. Meta-analysis of the TNFAIP3 region in psoriasis reveals a risk haplotype that is distinct from other autoimmune diseases. Genes Immun 16 (2015), 120–126.
45. Oeckinghaus, A., Wegener, E., Welteke, V., Ferch, U., Arslan, S.C., Ruland, J., et al. Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation. EMBO J 26 (2007), 4634–4645.
46. Oudot, T., Lesueur, F., Guedj, M., de Cid, R., McGinn, S., Heath, S., et al. An association study of 22 candidate genes in psoriasis families reveals shared genetic factors with other autoimmune and skin disorders. J Invest Dermatol 129 (2009), 2637–2645.
47. Pelzer, C., Cabalzar, K., Wolf, A., Gonzalez, M., Lenz, G., Thome, M., The protease activity of the paracaspase MALT1 is controlled by monoubiquitination. Nat Immunol 14 (2013), 337–345.
48. Qiao, Q., Yang, C., Zheng, C., Fontan, L., David, L., Yu, X., et al. Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: nucleation-induced filamentous assembly. Mol Cell 51 (2013), 766–779.
49. Qin, P., Zhang, Q., Chen, M., Fu, X., Wang, C., Wang, Z., et al. Variant analysis of CARD14 in a Chinese Han population with psoriasis vulgaris and generalized pustular psoriasis. J Invest Dermatol 134 (2014), 2994–2996.
50. Rebeaud, F., Hailfinger, S., Posevitz-Fejfar, A., Tapernoux, M., Moser, R., Rueda, D., et al. The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat Immunol 9 (2008), 272–281.
51. Ruefli-Brasse, A.A., French, D.M., Dixit, V.M., Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase. Science 302 (2003), 1581–1584.
52. Ruland, J., Duncan, G.S., Wakeham, A., Mak, T.W., Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity 19 (2003), 749–758.
53. Schmitt, A., Grondona, P., Maier, T., Brandle, M., Schonfeld, C., Jager, G., et al. MALT1 Protease activity controls the expression of inflammatory genes in keratinocytes upon zymosan stimulation. J Invest Dermatol 136 (2016), 788–797.
54. Scudiero, I., Vito, P., Stilo, R., The three CARMA sisters: so different, so similar: a portrait of the three CARMA proteins and their involvement in human disorders. J Cell Physiol 229 (2014), 990–997.
55. Scudiero, I., Zotti, T., Ferravante, A., Vessichelli, M., Vito, P., Stilo, R., Alternative splicing of CARMA2/CARD14 transcripts generates protein variants with differential effect on NF-kappaB activation and endoplasmic reticulum stress-induced cell death. J Cell Physiol 226 (2011), 3121–3131.
56. Sommer, K., Guo, B., Pomerantz, J.L., Bandaranayake, A.D., Moreno-Garcia, M.E., Ovechkina, Y.L., et al. Phosphorylation of the CARMA1 linker controls NF-kappaB activation. Immunity 23 (2005), 561–574.
57. Sugiura, K., Kitoh, T., Watanabe, D., Muto, M., Akiyama, M., Childhood-onset PsA in Down syndrome with psoriasis susceptibility variant CARD14 rs11652075. Rheumatology (Oxford) 54 (2015), 197–199.
58. Sugiura, K., Muto, M., Akiyama, M., CARD14 c.526G>C (p.Asp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort. J Invest Dermatol 134 (2014), 1755–1757.
59. Sun, L., Deng, L., Ea, C.K., Xia, Z.P., Chen, Z.J., The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 14 (2004), 289–301.
60. Tanner, M.J., Hanel, W., Gaffen, S.L., Lin, X., CARMA1 coiled-coil domain is involved in the oligomerization and subcellular localization of CARMA1 and is required for T cell receptor-induced NF-kappaB activation. J Biol Chem 282 (2007), 17141–17147.
61. te Velthuis, A.J., Admiraal, J.F., Bagowski, C.P., Molecular evolution of the MAGUK family in metazoan genomes. BMC Evol Biol, 7, 2007, 129.
62. Tejasvi, T., Stuart, P.E., Chandran, V., Voorhees, J.J., Gladman, D.D., Rahman, P., et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 132:Pt 1 (2012), 593–600.
63. Thome, M., Multifunctional roles for MALT1 in T-cell activation. Nat Rev Immunol 8 (2008), 495–500.
64. Uren, A.G., O'Rourke, K., Aravind, L.A., Pisabarro, M.T., Seshagiri, S., Koonin, E.V., et al. Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell 6 (2000), 961–967.
65. Wang, L., Guo, Y., Huang, W.J., Ke, X., Poyet, J.L., Manji, G.A., et al. Card10 is a novel caspase recruitment domain/membrane-associated guanylate kinase family member that interacts with BCL10 and activates NF-kappa B. J Biol Chem 276 (2001), 21405–21409.
66. Wiesmann, C., Leder, L., Blank, J., Bernardi, A., Melkko, S., Decock, A., et al. Structural determinants of MALT1 protease activity. J Mol Biol 419 (2012), 4–21.
67. Yim, K.M., Armstrong, A.W., Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms. [e-pub ahead of print] Rheumatol Int, 2016 http://dx.doi.org/10.1007/s00296-016-3487-2.
68. Yu, J.W., Hoffman, S., Beal, A.M., Dykon, A., Ringenberg, M.A., Hughes, A.C., et al. MALT1 protease activity is required for innate and adaptive immune responses. PLoS One, 10, 2015, e0127083.
69. Zhu, K., Shi, G., Liu, H., Zhu, C., Fan, Y., Variants of CARD14 gene and psoriasis vulgaris in southern Chinese cohort. An Bras Dermatol 91 (2016), 45–48.